Showing 1–24 of 68 results
Related Posts:
FDA Approves Vepdegestrant for ER+/HER2–, ESR1-Mutated Breast Cancer: A New Targeted Option
Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 6, 2026. Breast cancer treatment continues to evolve
READ MORE »May 6, 2026
First-Line Palbociclib Combination Boosts PFS in HR+/HER2+ mBC – PATINA Findings
n Medical Review: This article was reviewed by Dr. Sophie Reynolds on April 1, 2026.n n Metastatic breast cancer (mBC)
READ MORE »April 1, 2026
Atirmociclib and Fulvestrant Together Delay Cancer Progression in HR+/HER2– Cases
Medical Review: This article was reviewed by Dr. Sophie Reynolds on March 23, 2026. Advancements in breast cancer treatment continue
READ MORE »March 23, 2026